Pershing Square Holdings, Ltd. Increases Position In Valeant Pharmaceuticals International
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Buy Valeant Pharmaceuticals (VRX) Ahead of Investor Day Catalyst - Guggenheim
November 24, 2015 8:02 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and $195 on Valeant Pharmaceuticals (NYSE: VRX) saying the stock has bottomed and multiple expansion will drive shares higher. Chen recommends buying ahead of the December 16, 2015 investor day catalyst.
"Concerns regarding high-priced drugs and specialty pharmacies have weighed on VRX shares since mid-September,... More
Pershing Square Capital Affirms Lifting Valeant Pharma (VRX) Stake to 9.9%
November 23, 2015 5:28 PM ESTPershing Square Capital Management, L.P., the investment manager for Pershing Square Holdings, Ltd. has updated its Schedule 13D with the United States Securities and Exchange Commission, disclosing that various funds it manages increased their beneficial ownership of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), to 9.9% of shares outstanding.
... More